摘要
目的 :观察前列地尔 (前列腺素E1脂微球载体制剂 ,LipoPGE1,商品名 :凯时 )与低分子肝素 (商品名 :速避凝 )治疗不稳定型心绞痛 (UAP)的临床疗效及不良反应。方法 :将 118例UAP患者随机分为 2组 ,治疗组 (6 8例 )给予凯时加速避凝治疗 ;对照组 (5 0例 )给予速避凝治疗 ,2组均给予口服阿司匹林 (30 0mg·d-1)和抗心绞痛药物 ,疗程均为 10d。结果 :治疗组与对照组在住院 10d内治疗总有效率分别为 97.1%与 72 .0 % (P <0 .0 1) ,随访180d再发心绞痛、非致死性心肌梗死、心性死亡的发生率分别为 14.7%与 32 .0 % ,1.5 %与 10 .0 %和 1.5 %与8.0 % ,总的心性事件发生率为 5 0 .0 %与 17.7% (P <0 .0 1) ;2组均未出现明显不良反应。结论 :在常规治疗基础上凯时加速避凝治疗UAP能更有效地控制心绞痛发作 ,减少心性事件发生率。
Objective:To observe the efficacy and ADRs of alprostadil(Lipo prostaglandin E 1,Lipo PGE 1) plus low molecular weight heparin(LMWH) for treatment of unstable angina pectoria(UAP).Methods:118 patients with UAP were randomly divided to receive alprostadil plus LMWH ( n = 68) for 10d or LMWH( n =50) for 10d,in addition to aspirin and antianginal agents.Results:The total effective rate for active and control group was 97.1% and 72.0% respectively( P <0.01).The recurrent rate for angina pectoris,nonfatal myocardial infarction and cardiac death after 180d of treatment were 14.7%,1.5%,and 1.5% for active group and 32.0%,10.0% and 8.0% for control group respectively.No ADRs were observed in both groups.Conclusion:The alprostadil plus LMWH in addition to routine therapy can effectively control the attack of UAP and decrease the incidence of cardiac events.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2001年第9期699-701,共3页
Chinese Journal of New Drugs
